TGA GMP Clearance for Taiwan Manufacturers: Inspection and Certification Process

The Therapeutic Goods Administration (TGA) requires evidence of GMP compliance for all manufacturing sites producing therapeutic goods for the Australian market. Under Section 36 of the Therapeutic Goods Act 1989, no therapeutic good can be imported into Australia unless the overseas manufacturing site holds a valid TGA GMP clearance. This clearance confirms that the facility meets the manufacturing principles specified in the Therapeutic Goods (Manufacturing Principles) Determination, which aligns with PIC/S Guide to Good Manufacturing Practice PE 009-16.

GMP clearance applies to four categories of manufacturing: medicines (including complementary medicines/supplements), biologicals, medical devices of higher classification (Class III and AIMD), and active pharmaceutical ingredients (APIs). For Taiwan supplement and nutraceutical manufacturers, the relevant standard is the PIC/S GMP Guide for Medicinal Products, Annex 1 (sterile products if applicable) and Annex 7 (herbal medicinal products). Each manufacturing site requires its own GMP clearance, so a company with separate production and packaging facilities needs two separate clearances.

The TGA maintains a public database of overseas manufacturing sites with current GMP clearances, accessible through the TGA website's "Overseas GMP clearance" search tool. As of mid-2026, approximately 2,800 overseas sites hold valid TGA GMP clearances, with 45 from Taiwan. The clearance is valid for 3 years from the date of issue, after which the manufacturer must apply for re-clearance with updated documentation and potentially another inspection. Failure to maintain current GMP clearance results in automatic suspension of all ARTG listings associated with that manufacturing site.

Taiwan's pharmaceutical manufacturing sector benefits from TFDA's membership in PIC/S, which Taiwan joined in January 2013. This means Taiwan's PIC/S GMP inspections conducted by TFDA are recognized by other PIC/S members, including Australia. However, "recognition" does not mean automatic TGA clearance. The TGA evaluates PIC/S inspection reports from TFDA as supporting documentation but reserves the right to conduct its own inspection or request additional information. In practice, Taiwan facilities with clean TFDA PIC/S inspection histories receive TGA clearance more efficiently, often without a physical TGA inspection visit.

The GMP clearance application is submitted through the TGA Business Services (TBS) portal at tga.gov.au. The application requires an Australian sponsor, which is the entity holding the ARTG listing for the therapeutic good. The sponsor can be an Australian company or a foreign company with an authorized representative in Australia. The application fee is AUD 5,180 for a standard manufacturing site assessment. If a physical TGA inspection is required, additional fees of AUD 30,000-50,000 apply, covering inspector time, travel, and accommodation for a 3-5 day on-site audit at your Taiwan facility.

Required documentation for the GMP clearance application includes a current Site Master File (SMF) following the PIC/S format (PE 008-4), the most recent PIC/S GMP inspection report from TFDA (within the past 3 years), a list of products intended for the Australian market with their ARTG numbers or pending application numbers, a quality management system overview, and evidence of personnel qualifications including the Qualified Person (QP) or equivalent. The SMF alone typically runs 50-100 pages and must be in English, which takes 4-6 weeks to prepare if your existing documentation is in Chinese.

The TGA assessment process follows a defined timeline. Within 20 business days of application receipt, TGA assigns an evaluator and sends an acknowledgment. The evaluator reviews documentation for 40-60 business days and may issue a Request for Information (RFI) seeking clarification or additional documents. Responding to RFIs within 20 business days is critical to avoid application delays. If the evaluator determines a physical inspection is necessary, TGA coordinates with TFDA for a joint inspection or schedules a standalone TGA inspection, adding 3-6 months to the timeline. Total processing time from application to clearance ranges from 6 months (document review only) to 18 months (with physical inspection).

The TGA evaluator assesses your facility against nine key GMP areas: quality management system, personnel and training, premises and equipment, documentation and records, production operations, quality control laboratory, contracted activities, complaints and recalls, and self-inspection programs. Each area is rated as compliant, partially compliant, or non-compliant. A clearance is granted if all areas are rated compliant or partially compliant with an acceptable corrective action plan. Non-compliance in any critical area results in clearance refusal, requiring remediation and re-application at full fee.

The Site Master File (SMF) is the cornerstone document of your GMP clearance application. Following PIC/S format PE 008-4, the SMF must cover 11 chapters: general information about the manufacturer, quality management system, personnel, premises, equipment, documentation, production, quality control, distribution, complaints and product recall, and self-inspection. For Taiwan manufacturers, the SMF should emphasize export manufacturing experience, international certifications held (ISO 22000, FSSC 22000, ISO 17025 for lab), and specific quality controls applied to products destined for regulated markets.

Batch manufacturing records (BMRs) and batch packaging records (BPRs) must be available for TGA review. Prepare English-language examples of complete batch records for at least 3 representative products, showing all in-process controls, environmental monitoring data, and equipment cleaning validation. TGA inspectors particularly scrutinize deviation handling: maintain a deviation log showing all production deviations from the past 12 months, their root cause analysis, corrective and preventive actions (CAPA), and evidence of effectiveness checks. A well-documented deviation system with 100% closure rate within 30 days demonstrates GMP maturity.

Stability data requirements depend on the product type and intended shelf life. For complementary medicines, you need long-term stability data (25 degrees C/60% RH for 12-36 months depending on claimed shelf life) and accelerated stability data (40 degrees C/75% RH for 6 months). Stability-indicating analytical methods must be validated per ICH Q2(R2) guidelines. Budget AUD 5,000-15,000 per product for stability studies at accredited labs. Taiwan facilities accredited by the Taiwan Accreditation Foundation (TAF) under ISO 17025 can conduct stability testing in-house, but the analytical methods must be validated and audit-ready.

Additional supporting documents strengthen your application significantly. Include your annual product quality review (PQR) for products intended for Australia, showing trend analysis of critical quality attributes, process capability indices (Cpk >1.33 target), and out-of-specification (OOS) investigation reports. Provide validation master plans and completed validation reports for critical processes including blending uniformity, tablet compression, encapsulation, and packaging line clearance. A water system qualification report covering purified water generation, distribution loop monitoring, and microbial action/alert limits demonstrates infrastructure quality that TGA evaluators weight heavily in clearance decisions.

For Taiwan brands that cannot justify the 6-18 month timeline and AUD 35,000-55,000 cost of obtaining their own TGA GMP clearance, contract manufacturing with an Australian TGA-licensed facility is a practical alternative. Australia has approximately 180 TGA-licensed manufacturing facilities, with 35-40 offering contract manufacturing services for complementary medicines. Leading contract manufacturers include Pharmacare Laboratories (Kogarah NSW, minimum order 5,000 units), Vitex Pharmaceuticals (East Tamaki, with Australian operations), PharmaHealth Technologies (Fawkner VIC, minimum order 10,000 units), and Probiotec (Laverton North VIC, publicly listed, minimum order 20,000 units).

Contract manufacturing pricing in Australia runs AUD 2.50-8.00 per unit for tablets and capsules, AUD 4.00-12.00 per unit for liquid products, and AUD 3.00-9.00 per unit for powder sachets, depending on formulation complexity, batch size, and packaging requirements. These costs are 40-60% higher than Taiwan manufacturing costs, but the total cost of market entry is often lower when factoring in eliminated GMP clearance fees, reduced timeline (2-4 months vs 6-18 months), and immediate access to the Australian market. For initial market testing with 3-5 SKUs at volumes under 20,000 units, Australian contract manufacturing is typically the most cost-effective approach.

When selecting an Australian contract manufacturer, evaluate against six criteria: TGA license scope (confirm it covers your product types), minimum order quantities (MOQs range from 2,000 to 50,000 units), formulation development capability (some charge AUD 5,000-15,000 for new formulations, others include it in per-unit pricing), packaging options (blister, bottle, sachet, pouch), quality control laboratory capabilities (in-house vs outsourced testing), and lead time from order to delivery (typically 8-16 weeks for new products, 4-8 weeks for reorders).

A hybrid approach allows Taiwan brands to start with Australian contract manufacturing while simultaneously pursuing TGA GMP clearance for their Taiwan facility. Begin with contract manufacturing for your initial 3-5 SKUs to start generating revenue and building brand awareness. Use the 6-18 month GMP clearance timeline productively by gathering Australian market data, refining formulations based on consumer feedback, and building distribution relationships. Once your Taiwan facility receives GMP clearance, transition production to Taiwan for the higher-volume SKUs where the 40-60% manufacturing cost savings justify the logistics costs. Maintain the Australian contract manufacturer for low-volume specialty products and rush orders where the 14-18 day ocean freight timeline from Taiwan is too long.